SCHEMBL23923637

SCHEMBL23923637

CCCCCC/C=C\CCCCCCCC(=O)OC(CN)C(CN(C)C)OC(=O)CCCCCCC/C=C\CCCCCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.50
PRKCE Q02156 1/20 0.50
PRKCQ Q04759 1/20 0.50
PRKCD Q05655 1/20 0.50
FAAH O00519 4/20 0.48
SOAT1 P35610 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
MEN1 O00255 1/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
SLC6A5 Q9Y345 1/20 0.46
DGKA P23743 1/20 0.46
LPAR1 Q92633 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15668671 0.97 PRKCA (0.47) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL4451845 0.93 PRKCA (0.56) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL4458170 0.93 PRKCA (0.56) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL21014331 0.85 FAAH (0.61) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL26613661 0.85 LMNA (0.59) PRKCAPRKCEPRKCQPRKCDCYP1A2
SCHEMBL29168493 0.84 PRKCA (0.50) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL22367961 0.83 PRKCA (0.53) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL28372017 0.82 PRKCA (0.52) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL20985468 0.81 ALDH1A1 (0.53) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL992184 0.81 PRKCA (0.54) PRKCAPRKCEPRKCQPRKCDFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043639-B2 Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells MOLECULAR TRANSFER, INC. (US) 2024-07-23 US disclosed
US-20210323984-A1 POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS MOLECULAR TRANSFER, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043639-B2 Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells PHOSPHO1, MBOAT7, PLTP PRKCA 2533/4885PRKCE 2859/4885PRKCQ 2473/4885
US-20210323984-A1 POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS POLRMT, PHOSPHO1, MBOAT7 PRKCA 1994/4885PRKCE 2017/4885PRKCQ 1903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.